NobelDirect – Analysts` Report on Bone Loss Controversy

Merrill Lynch and UBS have released stock research reports regarding Nobel Biocare`s NobelDirect implant design. Several recent studies suggest more than 3mm of bone loss in 14-55% of patients. An expert panel advising the Swedish Medical Products Agency on the safety of the NobelDirect implant has responded to a recent Nobel Biocare rebuttal letter in a critical manner. The Merrill Lynch analyst suggests a NobelDirect withdrawal may be ahead.

This entry was posted in Implant Design. Bookmark the permalink.

Leave a Reply

Your email address will not be published. Required fields are marked *

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <s> <strike> <strong>